- Conditions
- Solid Tumors
- Interventions
- ME-344
- Drug
- Lead sponsor
- MEI Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 3,086
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor
- Interventions
- ALG.APV-527
- Drug
- Lead sponsor
- Aptevo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Port Saint Lucie, Florida
- Conditions
- Neoplasms
- Interventions
- BI 907828
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- Santa Monica, California • New Haven, Connecticut • Sarasota, Florida + 6 more
- Conditions
- Metastatic Neoplasm
- Interventions
- MK-8294, CD8 PET Tracer
- Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Hackensack, New Jersey • Houston, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more
- Conditions
- Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm
- Interventions
- GNX102
- Drug
- Lead sponsor
- GlycoNex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Newport Beach, California • Saint Paul, Minnesota + 3 more
- Conditions
- Non-Small Cell Lung Cancer, Malignant Solid Tumor
- Interventions
- enzastaurin, erlotinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more
- Conditions
- Solid Tumors
- Interventions
- INC280
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Chicago, Illinois • Detroit, Michigan + 2 more
- Conditions
- Solid Tumor
- Interventions
- S095029, S95029 and Sym021
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Grand Rapids, Michigan • Dallas, Texas • Houston, Texas + 1 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- DS-3939a
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- Sarasota, Florida • Locust Grove, Georgia • Westwood, Kansas + 9 more
- Conditions
- Solid Tumor
- Interventions
- BS006 Injection
- Drug
- Lead sponsor
- Binhui Biopharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Detroit, Michigan
- Conditions
- Solid Tumor, Adult
- Interventions
- FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cilengitide, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
- Interventions
- AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 14
- States / cities
- Duarte, California • Irvine, California • Santa Monica, California + 11 more
- Conditions
- Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas, Cancer of the Pancreas, Metastases, Metastatic Cancer, Metastatic Pancreatic Cancer, Pancreas Cancer, Pancreatic Cancer, Bone Metastases, Endocrine Cancer, Oncology, Oncology Patients, Solid Tumors, Advanced Malignancy
- Interventions
- AMG 479, Placebo, gemcitabine
- Drug
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 24
- States / cities
- Fullerton, California • La Jolla, California • Los Angeles, California + 18 more
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Interventions
- EP31670
- Drug
- Lead sponsor
- Epigenetix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Epofolate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Solid Tumor
- Interventions
- MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
- Conditions
- Solid Tumor
- Interventions
- Neratinib, Paclitaxel, Pertuzumab, Trastuzumab
- Drug
- Lead sponsor
- Michelle Melisko
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma, Chronic Lymphocytic Leukemia, Neoplasm Metastasis
- Interventions
- CC-115
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
- Conditions
- Advanced Solid Tumor
- Interventions
- GEN1286
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Grand Rapids, Michigan • San Antonio, Texas + 1 more
- Conditions
- Advanced Solid Tumors
- Interventions
- GEN1079
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Grand Rapids, Michigan • Lake Success, New York
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
- Interventions
- TH1902
- Drug
- Lead sponsor
- Theratechnologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Grand Rapids, Michigan • Gettysburg, Pennsylvania + 2 more
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- LUNA18, Cetuximab
- Drug
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Davis, California • Boston, Massachusetts • Detroit, Michigan + 9 more